Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Global Soil Mycobiome consortium dataset

ABSTRACT: The Global Soil Mycobiome consortium dataset

PROVIDER: PRJEB63550 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11608500.fastq.gz	Fastqsanger.gz
	ERR11608600.fastq.gz	Fastqsanger.gz
	ERR11608700.fastq.gz	Fastqsanger.gz
	ERR11608800.fastq.gz	Fastqsanger.gz
	ERR11608900.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 4978

Similar Datasets

Global Soil Mycobiome Consortium II dataset

Project description:Global Soil Mycobiome Consortium II dataset Targeted loci

| PRJNA1091046 | ENA

Global Soil Mycobiome Consortium II dataset

Project description:Eukaryome database

| PRJNA1072714 | ENA

Forest soil mycobiome

Project description:Forest soil mycobiome Metagenomic assembly

| PRJNA766339 | ENA

International Parkinson's Disease Consortium (IPDGC), NeuroX Dataset

Project description:International Parkinson's Disease Consortium (IPDGC), NeuroX Dataset

| PRJNA284551 | ENA

International Consortium for Blood Pressure GWAS 2011 discovery dataset

Project description:International Consortium for Blood Pressure GWAS 2011 discovery dataset

| PRJNA189296 | ENA

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190103 | GEO

NIDDK International IBD Genetics Consortium Repository Global Screening Array

Project description:NIDDK International IBD Genetics Consortium Repository Global Screening Array

| PRJNA695808 | ENA

NIDDK International IBD Genetics Consortium Repository Global Screening Array

Project description:NIDDK International IBD Genetics Consortium Repository Global Screening Array

| PRJNA695809 | ENA

NYGC ALS Consortium data

Project description:This SuperSeries is composed of the SubSeries listed below. Consortium contacts: Maria Pedersen: mpedersen@nygenome.org Hemali Phatnani: hphatnani@nygenome.org NYGC ALS Consortium: cgndhelp@nygenome.org

2019-09-20 | GSE137810 | GEO

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:We report the RNAseq of mouse pancreatic cancer cell lines with Kras ON vs Kras OFF. TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190468 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data